Neoplasms

Nervous System Diseases

Immune System Diseases

All Conditions

Musculoskeletal Diseases

Symptoms and General Pathology

Rare Diseases

Myasthenia Gravis

Muscle Weakness

Paresis

Asthenia

Muscular Diseases

Neuromuscular Manifestations

Neurologic Manifestations

Syndrome

Paraneoplastic Syndromes

Paraneoplastic Syndromes, Nervous System

Nervous System Neoplasms

Autoimmune Diseases

Autoimmune Diseases of the Nervous System

Neurodegenerative Diseases

Neuromuscular Junction Diseases

Neuromuscular Diseases

Participants will receive placebo followed by ALXN2050.

ALXN2050

Placebo

This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG).

Safety will be monitored throughout the study.

The study consists of a blinded 8-week Primary Evaluation Period (PEP) and a blinded 26-week Extended Treatment Period (ETP). After completion of 34 weeks of treatment, participants will enter an Open-label Extension (OLE) Period for up to 1.5 years.

Masking of treatment allocation will be observed until at least Week 34.

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Alexion Pharmaceuticals, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis	NCT05218096	Generalized Mya... Myasthenia Grav...	ALXN2050 Placebo	18 Years - 130 Years	Alexion Pharmaceuticals, Inc.
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis	NCT05218096	Generalized Mya... Myasthenia Grav...	ALXN2050 Placebo	18 Years - 130 Years	Alexion Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for alxn2050

Every month we try and update this database with for alxn2050 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for alxn2050

Every month we try and update this database with for alxn2050 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for alxn2050 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.